1. Urogenital testing |
Widely implement testing in asymptomatic key populations/communities |
Reduce testing of asymptomatic women and MSM |
|
1.1. In women, urogenital CT is prevalent, easily transmitted, and may cause complications |
1.3. Test implementation in ‘real-life’ does not achieve the desired benefits (of reducing prevalence and avoiding complications) |
|
1.2.With resources available, CT is easy to test |
1.4.Testing may also bring harm |
2. Extragenital testing |
Test more to reveal missed extragenital infections |
Reduce testing of asymptomatic CT with limited ‘relevance’ |
|
2.1. CT can occur at the pharyngeal and rectal sites in women and MSM |
2.3. Rectal CT might not always reflect a ‘true’ infection in women |
|
2.2. Rectal CT may comprise a ‘hidden’ reservoir of transmissible infections in women and MSM, and increase the risk for HIV acquisition and transmission in MSM |
2.4. Clinical impact of pharyngeal or rectal (non-LGV) CT may be limited |
3. Treatment |
Use azithromycin |
Use doxycycline |
|
3.1. Azithromycin is easy to use, safe, and widely applicable |
3.3. The risk of azithromycin treatment failure is high in rectal CT |
|
3.2. Azithromycin is effective in curing urogenital and pharyngeal CT |
3.4. Treatment, especially azithromycin, can cause AMR |